BenchSci, a world leader in AI solutions for preclinical life sciences research and development (R&D), recently announced a $95 million (US $70 million) Series D funding to expand their AI drug discovery platform ASCEND™, enabling scientists to discover biological connections, dramatically reduce trial-and-error experimentation and uncover risks early.